| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 299 | 283 | 270 | 285 | 353 | 363 | 352 | 371 | 336 | 390 | 375 | 328 | 471 | 428 | 355 | 351 | 514 | 458 | 428 | 442 | 566 | 514 | 483 | 482 | 667 | 549 | 483 | 508 | 684 |
| Expenses | 218 | 216 | 200 | 229 | 265 | 272 | 237 | 304 | 205 | 266 | 267 | 264 | 332 | 326 | 294 | 322 | 417 | 378 | 360 | 386 | 414 | 410 | 374 | 406 | 492 | 444 | 418 | 438 | 508 |
| EBITDA | 81 | 66 | 71 | 56 | 88 | 91 | 116 | 67 | 132 | 125 | 109 | 65 | 139 | 102 | 61 | 29 | 97 | 80 | 68 | 56 | 151 | 104 | 109 | 77 | 175 | 105 | 66 | 70 | 176 |
| Operating Profit % | 25 % | 21 % | 22 % | 15 % | 23 % | 21 % | 26 % | 9 % | 34 % | 28 % | 22 % | 16 % | 26 % | 18 % | 14 % | 6 % | 16 % | 15 % | 12 % | 11 % | 23 % | 16 % | 18 % | 12 % | 23 % | 14 % | 10 % | 11 % | 22 % |
| Depreciation | 9 | 9 | 8 | 8 | 9 | 10 | 9 | 9 | 9 | 10 | 9 | 10 | 10 | 10 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 | 14 | 13 | 16 | 15 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 72 | 57 | 63 | 48 | 78 | 80 | 106 | 57 | 121 | 114 | 99 | 54 | 128 | 91 | 51 | 19 | 87 | 69 | 57 | 45 | 141 | 93 | 98 | 65 | 163 | 90 | 51 | 53 | 160 |
| Tax | 23 | 16 | 17 | 13 | 22 | 26 | 32 | 1 | 30 | 26 | 24 | 7 | 31 | 19 | 15 | 9 | 16 | 17 | 16 | 15 | 31 | 23 | 18 | 19 | 44 | 18 | 14 | 15 | 38 |
| Net Profit | 49 | 40 | 46 | 35 | 56 | 54 | 74 | 56 | 92 | 88 | 75 | 47 | 98 | 72 | 36 | 10 | 71 | 52 | 41 | 31 | 110 | 70 | 79 | 46 | 119 | 72 | 37 | 39 | 121 |
| EPS in ₹ | 2.80 | 2.31 | 2.62 | 2.00 | 3.22 | 3.14 | 4.31 | 3.22 | 5.36 | 5.15 | 4.45 | 2.77 | 5.80 | 4.28 | 2.11 | 0.62 | 4.23 | 3.10 | 2.45 | 1.85 | 6.62 | 4.22 | 4.86 | 2.84 | 7.31 | 4.43 | 2.28 | 2.38 | 7.45 |
FDC
FDC
437.75
+2.05
(0.47%)
Key Fundamentals
Market Cap
7,093.60 Cr
EPS
16.39
PE Ratio
26.46
Dividend Yield
1.14 %
Industry
Healthcare 52 Week High
569.20
52 Week Low
366.25
PB Ratio
3.12
Debt to Equity
0.01
Sector
Pharmaceuticals Actual
Company News
View All News
FDC Limited announced the resignation of Vijay Dharmadatt Bhatt from his position as Chief Financial Officer and Key Managerial Personnel, effective October 20, 2025. Bhatt cited pursuing better prospects as the reason for his departure. The Board of Directors accepted his resignation and appointed Vishal Shah as the new CFO and Key Managerial Personnel, effective October 24, 2025. Shah brings approximately 20 years of work experience in finance portfolios including Business Finance, Costing, Financial Reporting and Treasury within the pharmaceutical industry. The appointment was approved based on recommendations from the Nomination and Remuneration Committee and Audit Committee.
FDC Ltd has received U.S. FDA approval for Pilocarpine Hydrochloride Eye Drops available in three formulations: 1%, 2%, and 4% concentrations in 15 ML packaging. This approval allows the pharmaceutical company to market these eye drop products in the United States market.
FDC Limited's Board approved unaudited financial results for the quarter ended June 30, 2025, showing revenue from operations of Rs 6,422.81 crores and net profit after tax of Rs 1,221.98 crores on standalone basis. The consolidated results showed revenue of Rs 6,484.06 crores with net profit of Rs 1,213.51 crores. Basic and diluted earnings per share stood at Rs 7.51 for standalone and Rs 7.45 for consolidated results. The Board also approved the reappointment of Mr. Ashok A. Chandavarkar as Executive Director for a five-year term from March 1, 2026 to February 28, 2031, subject to shareholder approval. Mr. Chandavarkar, who joined FDC in 1987 and became Executive Director in 1996, holds a Bachelor of Engineering (Mechanical) and has over 38 years of pharmaceutical industry experience. The company operates solely in the pharmaceuticals segment.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,679.10 | #1 3,98,049.70 | 38.75 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 61.71 | |
6,621.50 | 1,75,222.50 | 76.19 | 9,712.00 | 18.67 | 2,191 | 26.74 | 72.60 | |
1,577.60 | 1,26,768.90 | 23.67 | 28,409.50 | 7.12 | 5,291 | 9.88 | 60.63 | |
3,584.30 | 1,19,599.80 | 60.49 | 11,539.40 | 6.99 | 1,911 | 19.91 | 53.74 | |
1,255.90 | 1,03,508.80 | #1 18.25 | 33,741.20 | 16.73 | 5,725 | 1.26 | 48.97 | |
2,476.60 | 1,01,344.60 | 53.48 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 47.04 | |
987.65 | 99,073.80 | 21.09 | 23,511.00 | 18.55 | 4,615 | 2.60 | 45.37 | |
1,940.00 | 89,121.90 | 23.79 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 46.82 | |
5,581.50 | 66,047.70 | 28.61 | 13,458.30 | 3.70 | 2,216 | 21.39 | 63.11 | |
1,101.00 | 64,254.10 | 19.04 | 32,345.60 | 9.43 | 3,484 | -10.24 | 50.87 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
7.54 %
Net Income Growth
-12.55 %
Cash Flow Change
43.85 %
ROE
-19.59 %
ROCE
-17.09 %
EBITDA Margin (Avg.)
-12.26 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 1,149 | 1,266 | 1,468 | 1,505 | 1,640 | 1,813 | 1,956 | 2,270 | 2,343 | 2,468 | 2,714 |
| Fixed Assets | 393 | 675 | 678 | 674 | 682 | 674 | 689 | 705 | 699 | 680 | 852 |
| Current Assets | 502 | 523 | 708 | 722 | 740 | 927 | 934 | 1,000 | 1,027 | 1,067 | 1,089 |
| Capital Work in Progress | 29 | 20 | 6 | 13 | 12 | 24 | 19 | 105 | 198 | 262 | 137 |
| Investments | 273 | 325 | 491 | 471 | 585 | 665 | 790 | 886 | 806 | 843 | 1,028 |
| Other Assets | 454 | 246 | 293 | 348 | 360 | 451 | 458 | 575 | 640 | 684 | 698 |
| Total Liabilities | 1,149 | 1,266 | 1,468 | 1,505 | 1,640 | 1,813 | 1,956 | 2,270 | 2,343 | 2,468 | 2,714 |
| Current Liabilities | 188 | 163 | 179 | 212 | 179 | 246 | 204 | 272 | 312 | 311 | 362 |
| Non Current Liabilities | 24 | 20 | 18 | 18 | 16 | 19 | 19 | 42 | 50 | 60 | 71 |
| Total Equity | 936 | 1,083 | 1,270 | 1,276 | 1,445 | 1,547 | 1,734 | 1,956 | 1,981 | 2,097 | 2,281 |
| Reserve & Surplus | 919 | 1,065 | 1,252 | 1,259 | 1,428 | 1,530 | 1,717 | 1,940 | 1,966 | 2,081 | 2,265 |
| Share Capital | 18 | 18 | 18 | 18 | 18 | 17 | 17 | 17 | 17 | 16 | 16 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -9 | 4 | 11 | 1 | -8 | 10 | 1 | 7 | -14 | 2 | 26 |
| Investing Activities | -89 | -73 | -144 | 21 | -121 | -98 | -77 | -145 | 11 | -17 | -199 |
| Operating Activities | 128 | 174 | 155 | 150 | 112 | 250 | 207 | 162 | 155 | 221 | 318 |
| Financing Activities | -48 | -97 | 0 | -169 | -0 | -142 | -129 | -10 | -180 | -202 | -92 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 69.35 % | 69.35 % | 69.35 % | 69.36 % | 69.36 % | 69.50 % | 69.50 % | 69.50 % | 69.50 % | 69.50 % | 69.66 % | 69.66 % | 69.66 % | 69.66 % | 69.66 % | 69.66 % | 69.66 % | 69.66 % | 69.66 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 2.65 % | 2.51 % | 2.62 % | 2.67 % | 2.55 % | 2.41 % | 2.43 % |
| DIIs | 3.98 % | 4.28 % | 4.57 % | 5.37 % | 5.81 % | 6.00 % | 6.72 % | 7.76 % | 8.27 % | 8.95 % | 8.00 % | 7.61 % | 6.94 % | 6.73 % | 6.03 % | 6.08 % | 6.37 % | 7.17 % | 6.82 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 16.15 % | 16.82 % | 16.79 % | 16.61 % | 16.32 % | 16.35 % | 16.05 % | 15.42 % | 14.93 % | 15.59 % | 15.94 % | 16.12 % | 16.54 % | 16.71 % | 16.70 % | 16.57 % | 16.22 % | 16.17 % | 16.40 % |
| Others | 10.52 % | 9.55 % | 9.29 % | 8.67 % | 8.51 % | 8.15 % | 7.73 % | 7.32 % | 7.31 % | 5.96 % | 6.40 % | 6.61 % | 4.22 % | 4.39 % | 5.00 % | 5.02 % | 5.20 % | 4.59 % | 4.70 % |
| No of Share Holders | 0 | 40,327 | 49,335 | 49,889 | 53,582 | 86,503 | 65,318 | 63,172 | 57,012 | 56,717 | 56,928 | 55,341 | 52,377 | 50,634 | 55,400 | 55,228 | 53,880 | 54,445 | 54,157 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 2.25 | 0.00 | 0.00 | 0.8 | 0.00 | 0.00 | 0.00 | 0.00 | 5 |
| Dividend Yield (%) | 0.00 | 0.9 | 0.00 | 0.00 | 0.28 | 0.00 | 0.00 | 0.00 | 0.00 | 1.14 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 27 Sept 2023 |  Annual General Meeting | NA | 27 Sept 2023 | 377.90 | 374.70 |
| 26 Sept 2024 | Annual General Meeting | NA | 26 Sept 2024 | 560.65 | 559.40 |
| 06 Nov 2024 |  Quarterly Result Announcement | NA | 06 Nov 2024 | 516.70 | 541.05 |
| 22 Nov 2024 |  Dividend | ₹ 5.00 /share | 22 Nov 2024 | 541.05 | 485.50 |
| 12 Feb 2025 | Quarterly Result Announcement | NA | 12 Feb 2025 | 478.35 | 461.60 |
| 28 May 2025 | Quarterly Result Announcement | NA | 28 May 2025 | 467.35 | 459.50 |
| 07 Aug 2025 | Quarterly Result Announcement | NA | 07 Aug 2025 | 478.20 | 475.15 |
| 25 Sept 2025 | Annual General Meeting | NA | 25 Sept 2025 | 457.75 | 477.70 |
Announcements
Announcement under Regulation 30 (LODR)-Change in Management
2 days ago
2 days agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Oct 08, 2025Announcement Under Regulation 30-LODR (Intimation On ANDA Approval)Oct 04, 2025
Oct 04, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 26, 2025
Sep 26, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 25, 2025
Sep 25, 2025Closure of Trading WindowSep 25, 2025
Sep 25, 2025Reply To Exchange QuerySep 22, 2025
Sep 22, 2025Clarification sought from FDC LtdSep 22, 2025
Sep 22, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 01, 2025
Sep 01, 2025Intimation Of Book Closure And Cut-Off Date In Accordance With Regulation 42 Of SEBI (Listing Obligations And Disclosure Requirement) 2015Aug 29, 2025
Aug 29, 2025Business Responsibility and Sustainability Reporting (BRSR)Aug 29, 2025
Aug 29, 2025 Notice Of 85Th Annual General Meeting For F.Y 2024-25Aug 29, 2025
Aug 29, 2025Reg. 34 (1) Annual Report.Aug 29, 2025
Aug 29, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 28, 2025
Aug 28, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 07, 2025
Aug 07, 2025Board Meeting Outcome for Outcome For The Board Meeting Held On August 07 2025.Aug 07, 2025
Aug 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 04, 2025
Aug 04, 2025Board Meeting Intimation for Unaudited Standalone & Consolidated Financial Results For Quarter Ended June 302025.Aug 01, 2025
Aug 01, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 08, 2025
Jul 08, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Clarification On Spurt In VolumeJun 17, 2025
Jun 17, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 29, 2025
May 29, 2025Results-Financial Results For March 312025May 28, 2025
May 28, 2025Board Meeting Outcome for Outcome For The Board Meeting Held On May 282025May 28, 2025
May 28, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 26, 2025
May 26, 2025Board Meeting Intimation for Audited Standalone & Consolidated Financial Results Of The Company For The Quarter And Year Ended March 312025.May 22, 2025
May 22, 2025Announcement Under Regulation 30 (LODR) - Expansion Of Liquid Oral Facility At CompanyS Sinnar PlantApr 30, 2025
Apr 30, 2025Confirmation Regarding Company Not Falling Under Large Corporate Criteria As On March 31 2025Apr 24, 2025
Apr 24, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 14, 2025
Apr 14, 2025Closure of Trading WindowMar 26, 2025
Mar 26, 2025Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 19, 2025
Feb 19, 2025Integrated Filing (Financial)Feb 12, 2025
Feb 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 12, 2025
Feb 12, 2025Unaudited Financial Results For Quarter And Nine Months Ended 31St December 2024Feb 12, 2025
Feb 12, 2025Board Meeting Outcome for Outcome Of Board Meeting For Approving Unaudited Financial Results For Quarter And Nine Months Ended 31St December2024Feb 12, 2025
Feb 12, 2025Board Meeting Intimation for Unaudited Standalone & Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2024.Feb 07, 2025
Feb 07, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligation & Disclosure Requirements) Regulation 2015Jan 31, 2025
Jan 31, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 10, 2025
Jan 10, 2025 Intimation Of Change In Name Of CompanyS Registrar And Share Transfer Agent (RTA)Jan 02, 2025
Jan 02, 2025Intimation Regarding Approval Received From US FDA For ANDA- Cefixime 400 Mg TabletsDec 18, 2024
Dec 18, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 13, 2024
Dec 13, 2024Announcement Under Regulation 30 (LODR) - Intimation Of Company''s New Correspondence AddressDec 12, 2024
Dec 12, 2024Receipt Of Establishment Inspection Report (EIR) From US FDA With No Observations (Zero 483 S), As Closure Of Inspection Conducted At Company''s Manufacturing Facility Located At Baddi, Himachal Pradesh.Nov 13, 2024
Nov 13, 2024Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 07, 2024
Nov 07, 2024Corporate Action-Fixation Of Record Date For 1St Interim Dividend For FY 24-25.Nov 06, 2024
Nov 06, 2024Corporate Action-Board approves DividendNov 06, 2024
Nov 06, 2024Unaudited ( Standalone And Consolidated) Financial Results For Quarter And Half Year Ended On September 30,2024.Nov 06, 2024
Nov 06, 2024Board Meeting Outcome for Outcome Of Board Meeting For Approving Unaudited Financial Results For Quarter And Half Year Ended 3Oth September 2024Nov 06, 2024
Nov 06, 2024Board Meeting Intimation for Board Meeting Scheduled To Be Held On November 06,2024.Oct 28, 2024
Oct 28, 2024Mutual Fund Holdings
ICICI Prudential Multicap Fund Direct Plan-Growth 
Motilal Oswal Nifty Microcap 250 Index Fund Direct - Growth 
Bandhan BSE Healthcare Index Fund Direct-Growth 
Groww Nifty Total Market Index Fund Direct - Growth 
Angel One Nifty Total Market Index Fund Direct - Growth 
HDFC BSE 500 Index Fund Direct - Growth 
ITI Pharma and Healthcare Fund Direct - Growth 
Mirae Asset Nifty Total Market Index Fund Direct-Growth 
Nippon India Small Cap Fund Direct- Growth 
Tata India Pharma & Healthcare Fund Direct-Growth 
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth Technical Indicators
RSI(14)
Neutral 37.38
ATR(14)
Volatile 12.38
STOCH(9,6)
Oversold 14.84
STOCH RSI(14)
Neutral 23.77
MACD(12,26)
Bearish -1.99
ADX(14)
Weak Trend 14.38
UO(9)
Bearish 37.71
ROC(12)
Downtrend And Accelerating -1.03
WillR(14)
Oversold -87.34
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
